SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue declined to Rs. 9056.10 millions for the quarter ended September 2022 as compared to Rs. 9157.70 millions during the corresponding quarter last year.Profit after tax improved marginally to Rs. 1935.60  millions for the quarter ended September 2022 from Rs. 1875.60 millions of corresponding previous quarter.The company reported a good operating profit of 2790.80 millions compared to 2690.50 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 9056.10 9157.70 -1.11 16350.70 16176.10 1.08 32175.10 29204.70 10.17
Other Income 221.60 150.50 47.24 499.50 467.80 6.78 762.20 1101.90 -30.83
PBIDT 2790.80 2690.50 3.73 4548.00 4325.20 5.15 8320.50 7079.60 17.53
Interest 3.90 3.50 11.43 10.70 11.40 -6.14 19.90 35.30 -43.63
PBDT 2786.90 2687.00 3.72 4537.30 4313.80 5.18 8416.40 5318.30 58.25
Depreciation 163.60 174.30 -6.14 321.80 349.70 -7.98 681.90 786.00 -13.24
PBT 2623.30 2512.70 4.40 4215.50 3964.10 6.34 7734.50 4532.30 70.65
TAX 687.70 637.10 7.94 1123.60 1022.50 9.89 3968.70 1665.40 138.30
Deferred Tax -46.30 -37.80 22.49 -81.00 -72.60 11.57 -105.00 78.70 -233.42
PAT 1935.60 1875.60 3.20 3091.90 2941.60 5.11 3765.80 2866.90 31.35
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 30.82 29.38 4.89 27.82 26.74 4.03 25.86 24.24 6.68

Glaxosmithkline Phar Share Price

2491.40 28.65 (1.16%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×